Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients

OBJECTIVE: Bromocriptine mesylate (BRC), a dopamine D2 receptor agonist has been shown to confer neuroprotection, sustained motor function and slowed disease progression in mouse models of amyotrophic lateral sclerosis (ALS) Here we report a first in human trial in ALS. DESIGN: A multicenter, Riluzo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagata, Eiichiro, Ogino, Mieko, Iwamoto, Kounosuke, Kitagawa, Yasuhisa, Iwasaki, Yasuo, Yoshii, Fumihito, Ikeda, Joh-E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765990/
https://www.ncbi.nlm.nih.gov/pubmed/26910108
http://dx.doi.org/10.1371/journal.pone.0149509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765990/
https://www.ncbi.nlm.nih.gov/pubmed/26910108
http://dx.doi.org/10.1371/journal.pone.0149509

Ejemplares similares